Key result
RFCA is linked to ~4-point greater 6-month LVEF recovery in PMVT with heart failure.
Why the study?
Left ventricular recovery is an important treatment objective in patients with polymorphic ventricular tachycardia and heart failure, motivating an evaluation of 6-month LVEF after radiofrequency catheter ablation in patients with paired CMR measurements.
Does radiofrequency catheter ablation improve 6-month left ventricular ejection fraction in patients with clinically diagnosed polymorphic ventricular tachycardia and heart failure?
Cohort (n=92)
Blinded outcome assessment (imaging observers and laboratory personnel blinded to treatment group and visit)
No
Does radiofrequency catheter ablation improve 6-month left ventricular ejection fraction in patients with clinically diagnosed polymorphic ventricular tachycardia and heart failure?
Answers are grounded in this paper and cite their sources.
In a selected cohort of patients with polymorphic ventricular tachycardia and heart failure undergoing paired cardiac MRI, radiofrequency catheter ablation was associated with greater 6-month LVEF recovery, improved tissue mapping indices (native T1 and ECV), and reduced PVC burden.
Background Left ventricular recovery is an important treatment objective in patients with polymorphic ventricular tachycardia (PMVT) and heart failure. We examined 6-month left ventricular ejection fraction (LVEF) after radiofrequency catheter ablation (RFCA) in a retrospective cohort with paired cardiac magnetic resonance (CMR) measurements. Methods This single-center cohort included 92 patients with a clinical PMVT diagnosis and heart failure; 53 received RFCA and 39 did not. The primary outcome was baseline-adjusted 6-month LVEF. Propensity-score overlap weighting included 18 baseline covariates. HC3 standard errors, 2,000 treatment-stratified bootstrap resamples, reduced and expanded covariate sets, and ridge regularization assessed estimate stability. Native T1, extracellular volume fraction (ECV), premature ventricular complex (PVC) burden, biomarkers, and clinical events were secondary or exploratory outcomes. Results LVEF increased by 6.73 ± 2.15 percentage points with RFCA and 2.80 ± 1.86 without RFCA. The adjusted between-group difference was 3.70 percentage points (95% CI, 2.71–4.70); the propensity-refitting bootstrap interval was 2.78–4.53. Estimates incorporating hypertension and mineralocorticoid receptor antagonist use or ridge regularization ranged from 3.68 to 3.74 percentage points. Adjusted differences were −16.48 ms (95% CI, −20.44 to −12.53) for native T1, −1.26 percentage points (95% CI, −1.54 to −0.99) for ECV, and −6.77 percentage points (95% CI, −8.02 to −5.51) for PVC burden (all P < 0.001). Ventricular arrhythmia recurrence occurred in 5/53 vs. 10/39 patients; each group had two recurrences after the day-210 landmark. Conclusions RFCA was associated with greater 6-month LVEF recovery and lower recorded mapping indices and PVC burden in this selected paired-CMR cohort. Clinical-event comparisons were descriptive. The retrospective design, treatment selection, and requirement for paired CMR restrict the interpretation of these associations.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2026) conducted a cohort in Polymorphic ventricular tachycardia and symptomatic heart failure (n=92). Radiofrequency catheter ablation (RFCA) vs. Non-RFCA medical management was evaluated on Baseline-adjusted 6-month left ventricular ejection fraction (LVEF) (MD 3.70 percentage points, 95% CI 2.71-4.70, p=<0.001). Radiofrequency catheter ablation was associated with a 3.70 percentage-point greater 6-month LVEF recovery compared with non-RFCA management in patients with PMVT and HF.
Synapse has enriched 10 related papers. Consider them for comparative context: